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Editorial
The first successful case of renal transplantation in
humans was carried out more than 50 years ago [1].
Today, renal transplantation has become the treatment
of choice for many patients suffering from end-stage
renal failure. With the exception of transplantation
between two identical twins, renal transplant recipients
have to receive long-term immunosuppressive drugs
in order to prevent the host’s immune system from
rejecting the allograft kidney. Unfortunately, the
immunosuppressive drugs currently in use are still
relatively non-specific, and lifelong administration of
these drugs to transplant recipients is associated with
significant immune and non-immune toxicities.
Transplantation tolerance, the specific immune
unresponsiveness of the organ transplant recipient
towards the foreign histocompatibility antigens of the
transplanted organ without the need for ongoing im-
munosuppression, is regarded by many transplant
clinicians as the ultimate goal of clinical transplanta-
tion [2]. Over the past few decades, the transplant
community has devoted a great deal of effort to
developing strategies for tolerance induction in organ
transplantation. Excellent results of tolerance induc-
tion have been achieved, using a variety of methods,
in experimental animals including rodents and non-
human primates [3]. Mixed hematopoietic chimerism
is among one of the most promising approaches for
tolerance induction [4]. However, the application of
a mixed chimerism strategy to achieve transplantation
tolerance in humans has just begun over the past few
years. The conventional approach entails combined
hematopoietic stem cell and kidney transplantation with
myeloablative pre-conditioning [5,6].
In this issue of the Hong Kong Journal of
Nephrology, Vanikar et al report a novel and innovative
protocol for tolerance induction in renal transplant
recipients [7]. Their protocol consisted of pre-transplant
intrathymic inoculation of donor renal tissue, and
transplantation of donor hematopoietic stem cells with
non-myeloablative minimum conditioning. The authors
showed that patients who had undergone the tolerance
induction protocol, as compared to patients who had
undergone direct renal transplantation, had fewer and
milder rejection. In another paper in this same issue
of the Hong Kong Journal of Nephrology, the same
group of investigators demonstrated mixed lympho-
hematopoietic chimerism in seven patients who had
undergone the tolerance induction protocol [8]. All
these patients had stable graft function after complete
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withdrawal of immunosuppressive drugs. The results
of both studies are impressive and the protocol
developed by Vanikar et al has significant clinical
implications as it offers the opportunity to minimize
or withdraw immunosuppression after renal trans-
plantation.
There are a number of remarkable features about
the tolerance induction protocol developed by Vanikar
et al. First, a large dose of donor hematopoietic stem
cells was infused into the recipient in the absence of
immunosuppression before transplantation. It appears
that none of the study patients developed graft versus
host disease. Second, in contrast to other reports on
tolerance induction by mixed chimerism [5,6], no
myeloablative regimen was used before the trans-
plantation. It remains to be determined whether such
a protocol without myeloablative conditioning can
result in persistent and sustained mixed chimerism in
the renal transplant recipients. Larger scale prospective
studies should be carried out to confirm the long-term
safety and efficacy of this protocol.
Although tolerance induction should remain the
“holy grail” of clinical transplantation, the availability
of newer immunosuppressive drugs and refinement
of our current immunosuppressive protocols have
prompted some investigators to question the value of
tolerance induction in clinical practice. The work of
Vanikar et al and others [5–8] has, no doubt, brought
us one step closer towards true tolerance induction
in renal transplant recipients. However, much work
remains to be done if we are to make tolerance induc-
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